Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2/3 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 1Genitourinary 1

Conditions

Vasculitis 1Prostatic Neoplasms 1Neoplasms 1Lupus Erythematosus, Systemic 1Leukemia, Myeloid, Acute 1Glomerulonephritis 1COVID-19 1

Interventions

pembrolizumab 1270Specimen Handling 870Carboplatin 831Magnetic Resonance Spectroscopy 808Cyclophosphamide 802Cisplatin 728Nivolumab 658Paclitaxel 631Radiotherapy 573Gemcitabine 572Biopsy 529Bevacizumab 475Dexamethasone 440fludarabine 407Docetaxel 378venetoclax 370Oxaliplatin 365Capecitabine 356Fluorouracil 354atezolizumab 341durvalumab 334Rituximab 332Doxorubicin 316Radiosurgery 309Pemetrexed 305Drug Therapy 302Ipilimumab 294Standard of Care 293Etoposide 285Radiation 279

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Niclosamide × 1 year × Clear all
NCT03123978 2026-05-06

Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer

University of California, Davis

Phase 1 Completed
6 enrolled
Genitourinary

Prostatic Neoplasms

NCT05188170 2026-01-12

Niclosamide in Pediatric Patients With Relapsed and Refractory AML

Stanford University

Phase 1 Recruiting
16 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04870333 2025-06-20

PROTECT-V

Cambridge University Hospitals NHS Foundation Trust

Phase 2/3 Completed
2,240 enrolled

COVID-19, Glomerulonephritis, Lupus Erythematosus, Systemic, Neoplasms, Vasculitis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡